Evaluation of efficacy and safety after treatment of twice daily NovoMix30 in patients with type 2 diabetes A multi-centre, open-labelled, single-arm tria (Phase 4)

Trial Profile

Evaluation of efficacy and safety after treatment of twice daily NovoMix30 in patients with type 2 diabetes A multi-centre, open-labelled, single-arm tria (Phase 4)

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Insulin aspart/insulin protamine aspart (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top